Sodium butyrate, an effective HDAC inhibitor, can improve cognitive impairment in depression patients, possibly by upregulating thyroxine receptor (Ttr), downregulating serotonin 2A receptor (Htr2a), and upregulating neurotrophic factors (Yamawaki et al., 2012; Valvassori et al., 2014). The gene discussed is HTR2A; the disease is major depressive disorder.